Pharmacology of orthostatic hypotension in Parkinson’s disease: from pathophysiology to management

Authors: Pathak, Atul; Senard, Jean-Michel

Source: Expert Review of Cardiovascular Therapy, Volume 2, Number 3, May 2004 , pp. 393-403(11)

Publisher: Expert Reviews

Buy & download fulltext article:

OR

Price: $73.00 plus tax (Refund Policy)

Abstract:

Orthostatic hypotension is highly prevalent in the elderly, and affects up to 20% of patients with Parkinson’s disease. Pharmacological approaches help to demonstrate that Parkinson’s disease is a primary autonomic failure with involvement of the peripheral autonomic nervous system as shown by decreased [123I] meta-iodobenzylguanidine cardiac uptake and preserved growth hormone response to clonidine. No specific clinical trial has evaluated efficacy of antihypotensive drugs in Parkinson’s disease. End point of treatment should be a reduction in postural symptoms. Midodrine (Proamatin®, Roberts Pharmaceutical), a vasoconstrictor and fludrocortisone (Florinef®, Bristol–Myers Squibb), a volume expander are first choice drugs. No data are available on their effects on orthostatic hypotension-related morbidity. The usefulness of other drugs remains to be demonstrated. This review will highlight the importance of nonpharmacological measures in the management of orthostatic hypotension in Parkinson’s disease.
More about this publication?
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page